Purdue Pharma to cease marketing Oxycontin and opioid drugs in the US.
Purdue Pharma, the maker of OxyContin ,is to stop promoting the drug to doctors and halve its salesforce, as it faces a growing number of lawsuits over its role in the US opioid crisis. Purdue Pharma said its remaining 200 sales representatives would no longer visit doctors� offices to promote its opioid drugs.
OxyContin is Purdue�s biggest-selling drug though sales are down from $2.8bn five years earlier. Purdue said: �We have restructured and significantly reduced our We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers.�
Comment: In 2016, opioids, including prescription drugs, fentanyl and heroin, killed more than 42,000 people, according to the Centers for Disease Control, with more than 40% of overdose deaths involving a prescription opioid. Deaths from prescription drugs alone have quadrupled since 1999, the CDC reported.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.